Ibrutinib has also been described to lessen Continual lymphocytic leukemia cell chemotaxis to the chemokines CXCL12 and CXCL13, and inhibit mobile adhesion subsequent stimulation in the B-cell receptor (BCR). Before getting ibrutinib, inform your Health care service provider about all of your med